Related Experiment Video
Updated: Mar 9, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cardiac complications in cancer treatment - A review
Xianchi Li1, Min Liu1, Rongrong Sun1
1Xuzhou Central Hospital, Xuzhou 221009, Jiangsu Province, China; The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, Jiangsu Province, China; Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, Jiangsu Province, China; Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, Jiangsu Province, China.
Abstract:
Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against cancer have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her cancer but die due to heart failure. Recent research has been focused on the development of new avenues and technological advancements to monitor clinical cardiotoxicity and cardiac dysfunction due to anticancer treatment. These newer treatment options are also increasingly effective and are focused more on post-cancer life. The present review article expands the current view of cardiac complications involved in cancer treatment along with the recent developments in the area.
Insights
Cancer therapies can cause heart problems, leading to heart failure even after cancer survival. New research focuses on monitoring and managing this cardiotoxicity for better patient outcomes.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Effective cancer treatments, particularly targeted therapies, are increasingly linked to cardiac dysfunction.
- Patients may survive cancer only to develop fatal heart failure, highlighting a critical survivorship issue.
Purpose of the Study:
- To review current understanding of cardiac complications arising from cancer treatments.
- To discuss recent advancements in monitoring and managing treatment-induced cardiotoxicity.
Main Methods:
- This review synthesizes findings from recent research and clinical studies.
- It examines technological advancements in the detection and management of cardiac dysfunction.
Main Results:
- Anticancer therapies, including novel targeted agents, pose significant risks of cardiotoxicity.
- Early detection and monitoring are crucial for mitigating long-term cardiac damage.
Conclusions:
- Managing cardiotoxicity is essential for improving long-term survival and quality of life in cancer patients.
- Continued research into novel monitoring and therapeutic strategies is vital.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Pericarditis IV: Nursing Management
Cardiomyopathy V: Interprofessional Care

